The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications

Journal of Psychosocial Nursing and Mental Health Services

Volumn 52, Issue 7, 2014, Pages 30-37

  Jacobowitz, William ^a   Derbabian, Barbara ^b   Saunders, Anne ^c  

^a ADELPHI UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c Donald and Barbara Zucker School of Medicine at Hofstra Northwell   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGE; CALORIC RESTRICTION; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIET THERAPY; DRUG EFFECTS; FEMALE; HUMAN; MALE; MENTAL DISORDERS; NURSING EDUCATION; OBESITY; SEX DIFFERENCE; TIME; WEIGHT GAIN;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CALORIC RESTRICTION; EDUCATION, NURSING, CONTINUING; FEMALE; HUMANS; MALE; MENTAL DISORDERS; OBESITY; RISPERIDONE; SEX FACTORS; TIME FACTORS; WEIGHT GAIN;

EID: 84904337438     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20140421-01     Document Type: Article

References (20)

1. Allison, D.B., & Casey, D.E. (2001). Antipsy- chotic induced weight gain: A literature re- view. Journal of Clinical Psychiatry, 62(Suppl. 7), 22-31.
2. Allison, D.B., Mentore, J.L., Heo, M., Chan- dler, L.P., Cappelleri, J.C., Infante, M.C., & Weiden, P.J. (1999). Antipsychotic-induced weight gain: A comprehensive research syn- thesis. American Journal of Psychiatry, 156, 1686-1696.
3. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum.
4. Edward, K., Rasmussen, B., & Munro, I. (2010). Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes. Archives of Psychiatric Nursing, 24, 46-53. doi:10.1016/j.apnu.2009.04.009
5. Evans, S., Newton, R., & Higgins, S. (2005). Nu- tritional intervention to prevent weight gain in patients commenced on olanzapine: A ran- domized controlled trial. Australian and New Zealand Journal of Psychiatry, 39, 479-486.
6. Faul, F., Erdfelder, E., Buchner, A., & Lang, A.G. (2009). Statistical power analyses using G*Power 3.1: Tests for correlation and regres- sion analyses. Behavior Research Methods, 41, 1149-1160. doi:10.3758/BRM.41.4.1149
7. Fleischhaker, C, Heiser, P., Hennighausen, K., Herpertz-Dahlmann, B., Holtkamp, K., Mehler-Wex, C., Warnke, A. (2007). Weight gain associated with clozapine, olan- zapine and risperidone in children and ado- lescents. Journal of Neural Transmission, 114, 273-280. doi:10.1007/s00702-006-0602-7
8. Ganguli, R., Brar, J.S., & Ayrton, Z. (2001). Weight gain over 4 months in schizophrenia patients: A comparison of olanzapine and risperidone. Schizophrenia Research, 49, 261-267.
9. Gebhardt, S., Haberhausen, M., Heinzel- Gutenbrunner, M., Gebhardt, N., Rem- schmidt, H., Krieg, J., Theisen, F. (2009). Antipsychotic-induced body weight gain: Predictors and a systematic categoriza- tion of the long-term weight course. Jour- nal of Psychiatric Research, 43, 620-626. doi:10.1016/j.jpsychires.2008.11.001
10. Gentile, S. (2006). Long-term treatment with atypical antipsychotics and the risk of weight gain: A literature analysis. Drug Safety, 29, 303-319.
11. Haddad, P., & Sharma, S.G. (2007). Adverse effects of atypical antipsychotics differential risk and clinical implications. CNS Drugs, 21, 911-936.
12. Pendlebury, J., Haddad, P., & Dursun, S. (2005). Evaluation of a behavioural weight manage- ment programme for patients with severe mental illness: 3 year results. Human Psy- chopharmacology, 20, 447-448. doi:10.1002/ hup.707
13. Perez-Iglesias, R., Crespo-Facorro, B., Martinez- Garcia, O., Ramirez-Bonilla, M.L., Alvarez- Jimenez, M., Pelayo-Teran, J.M., Vazquez- Barquero, J.L. (2008). Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clini- cal trial in a drug-naïve population. Schizo-phrenia Research, 99, 13-22. doi:10.1016/j. schres.2007.10.022
14. Peters, R.M. (2012). Quantitative designs: Us-ing numbers to provide evidence. In N.A. Schmidt & J.M. Brown (Eds.), Evidence-based practice for nurses (pp. 165-186). Sudbury, MA: Jones & Bartlett.
15. Poulin, M., Chaput, J., Simard, S., Vincent, P., Bernier, J., Gauthier, Y., Tremblay, A. (2007). Management of antipsychotic- induced weight gain: Prospective naturalistic study of the effectiveness of a supervised exer- cise programme. Australian and New Zealand Journal of Psychiatry, 41, 980-989.
16. Ratzoni, G., Gothelf, D., Brand-Gothelf, A., Reidman, J., Kikinson, L., Gal, G., Weiz- man, R. (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 337-343.
17. Saddichha, S., Ameen, S., & Akhtar, S. (2008). Predictors of antipsychotic-induced weight gain in fi rst-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperi- done, and haloperidol. Journal of Clinical Psychopharmacology, 28, 27-31. doi:10.1097/ jcp.0b013e3181602fe6
18. Strassnig, M., Miewald, J., Keshavan, M., & Ganguli, R. (2007). Weight gain in newly diagnosed fi rst-episode psychosis patients and healthy comparisons: One-year analysis. Schizophrenia Research, 93, 90-98.
19. Wirshing, D.A., Wirshing, W.C., Kysar, L., Ber-isford, M.A., Goldstein, D., Pashdag, J., Marder, S.R. (1999). Novel antipsychotics: Comparison of weight gain liabilities. Journal of Clinical Psychiatry, 60, 358-363.
20. Zipursky, R.B., Gu, H., Green, A.K., Perkins, D.O., Tohen, M.F., McEvoy, J.P, Lieber- man, J.A. (2005). Course and predictors of weight gain in people with first-episode psy- chosis treated with olanzapine or haloperidol. British Journal of Psychiatry, 187, 537-543.